99.9% was obtained by thermal neutron bombardment (4×1013n/cm2.s) of 176Yb target through the 176Yb(n,γ) 177Yb 177Lu process. The method of separation of 177Lu from macro amount of Yb target was based on extraction chromatographic (EXC). The extractant used in resin was di(2-ethylhexyl) orthophosphoric acid (HDEHP). Finally, (177Lu) with a specific activity of 230.1 MBq (6.22 mCi) was prepared without the addiation of any carrier radionuclide. The process provides a separation yield of 75% 177Lu and a decontamination factor of 2000. The whole process to prepare NCA 177Lu takes almost 1.5 hours. The resultant NCA 177Lu can be used for preparation of NCA 177Lu labeled radiotherapeuticals. ]]>
p. 1−8
2676-5861
Vol.37/No.3
p. 9−17
2676-5861
Vol.37/No.3
p. 18−28
2676-5861
Vol.37/No.3
p. 29−40
2676-5861
Vol.37/No.3
p. 41−48
2676-5861
Vol.37/No.3
p. 49−61
2676-5861
Vol.37/No.3
98%. In order to determine the radiolabeling yield (or metallation) radio thin layer chromatography (RTLC) and high performance liquid chromatography (HPLC) were used (with the radiochemical yield of >99% for both methods). The radiolabeled compound was injected to the healthy rats and the biodistribution studies were performed using scarification. The single photon emission computed tomography (SPECT) imaging within 2-24h shows the accumulation of 111In-THPP in the kidneys, compared to other organs. 111In-THPP is essentially excreted via kidneys. Due to relatively low liver uptake and kidney wash-out, 111In-THPP could be a potential agent for imaging.]]>
p. 62−69
2676-5861
Vol.37/No.3
p. 70−77
2676-5861
Vol.37/No.3
p. 78−86
2676-5861
Vol.37/No.3
p. 87−95
2676-5861
Vol.37/No.3